Konu "ALK" için listeleme

Toplam kayıt 3, listelenen: 1-3

    • Effect of Asbestos Exposure on the Frequency of EGFR Mutations and ALK/ROS1 Rearrangements in Patients With Lung Adenocarcinoma A Multicentric Study 

      Yilmaz, Senay; Demirci, Nilgun Yilmaz; Metintas, Selma; Zamani, Adil; Karadag, Mehmet; Guclu, Ozge A.; Kabalak, Pinar Akin; Yilmaz, Ulku; Ak, Guntulu; Kizilgoz, Derya; Ozturk, Akin; Yilmaz, Ufuk; Batum, Ozgur; Kavas, Murat; Serifoglu, Irem; Unsal, Meftun; Komurcuoglu, Berna E.; Cengiz, Tuba Inal; Ulubay, Gaye; Ozdemirel, Tugce S; Ozyurek, Berna A.; Kavurgaci, Suna; Alizoroglu, Dursun; Celik, Pinar; Erdogan, Yurdanur; In, Erdal; Aksoy, Asude; Altin, Sedat; Gunluoglu, Gulsah; Metintas, Muzaffer (2021)
      Objective: The aim of this study is to investigate the effect of asbestos exposure on cancer-driver mutations. Methods: Between January 2014 and September 2018, epidermal growth factor receptor (EGFR), anaplastic lymphoma ...

    • GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients 

      Sezer, Ahmet; Ozyilkan, Ozgur (2020)
      Lorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions. The FDA has approved lorlatinib for TKI-pretreated ALK(+) NSCLC, while its approval for ROS1( + ) is still pending. Here we ...

    • Precision medicine for metastatic colorectal cancer: an evolving era 

      Guler, Irem; Askan, Gokce; Klostergaard, Jim; Sahin, Ibrahim Halil (2019)
      Introduction: Metastatic colorectal cancer (CRC) remains a dilemma for cancer researchers with an increasing incidence in the younger patient population. Until the last decade, limited therapeutic options were available ...